Literature DB >> 30844556

Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.

Dong Yeon Jeong1, Seung Kim2, Min Ji Son1, Chei Yun Son3, Jong Yeob Kim1, Andreas Kronbichler4, Keum Hwa Lee5, Jae Il Shin6.   

Abstract

Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). We conducted a comprehensive review of meta-analyses to summarize the reported effectiveness of different drugs for IBD. We performed a literature search and a total of 110 meta-analyses from 66 articles were summarized and re-analyzed (62 in UC and 48 in CD). In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD. The use of immunomodulatory agents in the induction or maintenance phase of UC and CD using immunomodulators appeared to be more effective than placebo, but the results were impacted by small number of patients, discordant results with the largest study and risk of biases. Anti-TNF-α and anti-integrin therapeutic antibodies in both, induction and maintenance, showed a better efficacy than placebo in a large proportion of patients analyzed. Other agents, such as probiotics, antibiotics, omega-3, were shown to be more effective than placebo, but the same issues arose as stated above with the use of immunomodulatory agents. In conclusion, we performed a comprehensive review of meta-analysis on comparative efficacy of pharmacotherapy used in the management of IBD. Our review will augment our understanding of the treatment of UC and CD by providing a guideline for interpreting the statistically significant findings and discusses the optimal choice for IBD treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumor necrosis factor-α; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 30844556     DOI: 10.1016/j.autrev.2019.03.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  27 in total

Review 1.  Head-to-head trials in inflammatory bowel disease: past, present and future.

Authors:  Lieven Pouillon; Simon Travis; Peter Bossuyt; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-17       Impact factor: 46.802

Review 2.  The promise of the gut microbiome as part of individualized treatment strategies.

Authors:  Daniel A Schupack; Ruben A T Mars; Dayne H Voelker; Jithma P Abeykoon; Purna C Kashyap
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

3.  Munronoid I Ameliorates DSS-Induced Mouse Colitis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Via Modulation of NLRP3.

Authors:  Xingyu Ma; Qianqian Di; Xiaoli Li; Xibao Zhao; Ruihan Zhang; Yue Xiao; Xunwei Li; Han Wu; Haimei Tang; Jiazheng Quan; Zherui Wu; Weilie Xiao; Weilin Chen
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

4.  The Association of Gut Microbiota and Treg Dysfunction in Autoimmune Diseases.

Authors:  Yuying Liu; Dat Q Tran; John William Lindsey; Jon Marc Rhoads
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 5.  Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products.

Authors:  Karma Yeshi; Roland Ruscher; Luke Hunter; Norelle L Daly; Alex Loukas; Phurpa Wangchuk
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

6.  Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota.

Authors:  Zhongmei Sun; Junxiang Li; Yi Dai; Wenting Wang; Rui Shi; Zhibin Wang; Panghua Ding; Qiongqiong Lu; Hui Jiang; Wenjing Pei; Xingjie Zhao; Yi Guo; Jiali Liu; Xiang Tan; Tangyou Mao
Journal:  Front Microbiol       Date:  2020-04-30       Impact factor: 5.640

7.  Dietary Supplementation with Spray-Dried Porcine Plasma Attenuates Colon Inflammation in a Genetic Mouse Model of Inflammatory Bowel Disease.

Authors:  Lluïsa Miró; Concepció Amat; Cristina Rosell-Cardona; Joy M Campbell; Javier Polo; Anna Pérez-Bosque; Miquel Moretó
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

8.  Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease.

Authors:  Shixian Hu; Werna T Uniken Venema; Harm-Jan Westra; Arnau Vich Vila; Ruggero Barbieri; Michiel D Voskuil; Tjasso Blokzijl; Bernadien H Jansen; Yanni Li; Mark J Daly; Ramnik J Xavier; Gerard Dijkstra; Eleonora A Festen; Rinse K Weersma
Journal:  Nat Commun       Date:  2021-02-18       Impact factor: 14.919

Review 9.  Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.

Authors:  Aysha H Al-Ani; Ralley E Prentice; Clarissa A Rentsch; Doug Johnson; Zaid Ardalan; Neel Heerasing; Mayur Garg; Sian Campbell; Joe Sasadeusz; Finlay A Macrae; Siew C Ng; David T Rubin; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2020-05-26       Impact factor: 9.524

10.  Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease.

Authors:  Mengque Xu; Mengsha Cen; Xiaoli Chen; Haotian Chen; Xing Liu; Qian Cao
Journal:  Biomed Res Int       Date:  2019-12-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.